We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Stunned by Proposed Change to Biosimilar Exclusivity Period
Industry Stunned by Proposed Change to Biosimilar Exclusivity Period
March 2, 2011
The drug industry and stakeholders have been taken aback by a measure in President Barack Obama’s proposed fiscal 2012 budget that would lower the exclusivity period for generic biologics from 12 to seven years.